AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24628565 — intervention group
Group type: EXPERIMENTAL
Intervention: PICO50
Number of subjects: 25
Study 24628565 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex Line Draw Plus
Number of subjects: 25
Study 24628779 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterograde peak diastolic flow velocities (pDV) in septal perforating branches
Number of subjects: 108
Study 24628779 — intervention group
Group type: EXPERIMENTAL
Intervention: pDV ≥ 0.57 m/sec
Number of subjects: 108
Study 24628779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of several parameters indicating collateral flow
Number of subjects: 108
Study 24628963 — intervention group
Group type: EXPERIMENTAL
Intervention: XELBEVOCT regimen (octreotide LAR 20 mg monthly, metronomic capecitabine 2000 mg daily, intravenous bevacizumab 5 mg/kg every 2 weeks for 9 months)
Number of subjects: 45
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item abbreviated QLS
Number of subjects: 1427
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-item abbreviated QLS
Number of subjects: 1427
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: Full QLS
Number of subjects: 1427
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item and 4-item abbreviated QLS
Number of subjects: 1427
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amotivation/apathy
Number of subjects: 1427
Study 24630140 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal change
Number of subjects: 1427
Study 24630875 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based PFO closure
Number of subjects: 47
Study 24630875 — intervention group
Group type: COMPARATOR
Intervention: PFO group
Number of subjects: 47
Study 24631328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana® Press (SP)
Number of subjects: 362
Study 24631409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100mg or 40mg)
Number of subjects: 65
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high-risk (hr) HPV infection in women with primary CIN3+ and recurrent CIN2+
Number of subjects: 58
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HPV16- and HPV18-infected CIN3+
Number of subjects: 58
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV33-infected CIN3+
Number of subjects: 58
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HPV type-infected CIN3+
Number of subjects: 58
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine post-conization hr-HPV DNA testing and cervical cytology
Number of subjects: 58
Study 24631451 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent vaccination
Number of subjects: 58
Study 24631511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque rupture
Number of subjects: 660
Study 24631511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with subclinical, nonculprit plaque ruptures
Number of subjects: 660
Study 24631512 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting myocardial tissue Doppler velocities (s', a', e')
Number of subjects: 225
Study 24631512 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting eas index
Number of subjects: 225
Study 24631512 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress testing
Number of subjects: 225
Study 24632880 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo surgery
Number of subjects: 100
Study 24633206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline therapy for ≥1 month (mean, 255.0 ± 265.7 days)
Number of subjects: 52
Study 24633206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline therapy for ≥1 month (mean, 143 ± 123 days)
Number of subjects: 52
Study 24633206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline therapy
Number of subjects: 52
Study 24633881 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atrial fibrillation (SCAF) >6 minutes in duration
Number of subjects: 2580
Study 24633881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF detected before stroke or systemic embolism
Number of subjects: 2580
Study 24633881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF detected within 30 days before stroke or systemic embolism
Number of subjects: 2580
Study 24633881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF detected >30 days before stroke or systemic embolism
Number of subjects: 2580
Study 24633881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF detected only after stroke
Number of subjects: 2580
Study 24634371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2458
Study 24634374 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes with DC vaccination (n = 10)
Number of subjects: 14
Study 24634374 — intervention group
Group type: COMPARATOR
Intervention: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes without DC vaccination (n = 3)
Number of subjects: 14
Study 24634374 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly manufactured TCR transgenic T cells
Number of subjects: 14
Study 24635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy with hypertonic dextrose and morrhuate sodium injections (15% dextrose and 5% morrhuate sodium) at peri-articular tendon and ligament insertions, and a single intra-articular injection of 6 mL 25% dextrose.
Number of subjects: 38
Study 24635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy with hypertonic dextrose and morrhuate sodium injections.
Number of subjects: 38
Study 24635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure opioid medication use.
Number of subjects: 38
Study 24635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant satisfaction after prolotherapy injections.
Number of subjects: 38
Study 24636025 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD with deficits in both SWM and SOC tasks (n=121)
Number of subjects: 511
Study 24636025 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD with deficit in either SWM or SOC task (n=185)
Number of subjects: 511
Study 24636025 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD without deficits in SWM or SOC task (n=205)
Number of subjects: 511
Study 24636025 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD controls (n=124)
Number of subjects: 511
Study 24636429 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem (500mg intravenously, infused over 1h or 4h every 8h for 5-14 days)
Number of subjects: 216
Study 24637635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) administered before tumor resection
Number of subjects: 27
Study 24637635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab pharmacokinetics
Number of subjects: 27
Study 24637635 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index percentile
Number of subjects: 27
Study 24637689 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir and mericitabine combination treatment
Number of subjects: 89
Study 24638012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus chlorambucil (R-chlorambucil)
Number of subjects: 100
Study 24638072 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive chemotherapy for HIV-1 related lymphoma
Number of subjects: 9
Study 24639271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony-forming units, n = 168)
Number of subjects: 336
Study 24639720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline used for semen processing (group I)
Number of subjects: 120
Study 24639720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline used for semen processing (group IIIA)
Number of subjects: 120
Study 24639720 — intervention group
Group type: COMPARATOR
Intervention: No pentoxifylline used for semen processing (group II)
Number of subjects: 120
Study 24639720 — intervention group
Group type: COMPARATOR
Intervention: No pentoxifylline used for semen processing (group IIIB)
Number of subjects: 120
Study 24641955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0
Study 24641955 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (cyclophosphamide, glucocorticosteroids, mycophenolate mofetil)
Number of subjects: 0
Study 24641955 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin blockade
Number of subjects: 0
Study 24642016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of autologous bone marrow-derived total nucleated cells (TNC)
Number of subjects: 18
Study 24642016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of autologous bone marrow-derived total nucleated cells (TNC)
Number of subjects: 18
Study 24642016 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment at 6 months post-therapy
Number of subjects: 18
Study 24642140 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Directions 2 (HD2)
Number of subjects: 2440
Study 24642140 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Directions 2 plus 2 brief telephone coaching calls (HD2+CC)
Number of subjects: 2440
Study 24642140 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2440
Study 24642247 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg intravenously approximately every 3 weeks over 30 minutes
Number of subjects: 29
Study 24642467 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic repolarization dynamics (PRD)
Number of subjects: 2965
Study 24642467 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological blockade of sympathetic nervous system activity
Number of subjects: 2965
Study 24642999 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine measurement of fractional flow reserve (FFR) during coronary angiography (CA)
Number of subjects: 200
Study 24643408 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery interadventitial diameter
Number of subjects: 6255
Study 24643408 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery interadventitial diameter after adjustment for risk factors and common carotid IMT
Number of subjects: 6255
Study 24643408 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid IMT
Number of subjects: 6255
Study 24643601 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer cutoff (age × 10)
Number of subjects: 3346
Study 24643601 — intervention group
Group type: COMPARATOR
Intervention: Fixed D-dimer cutoff of 500 µg/L
Number of subjects: 3346
Study 24643960 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (rIPC) with circulating nitrite
Number of subjects: 100
Study 24643960 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological and genetic inhibition of nitric oxide/nitrite generation
Number of subjects: 100
Study 24643960 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of plasma from healthy volunteers subjected to rIPC
Number of subjects: 100
Study 24643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated highly positive script
Number of subjects: 105
Study 24646518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 300,000 units cholecalciferol administered at baseline and 8-weeks
Number of subjects: 26
Study 24646562 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev)
Number of subjects: 49
Study 24646562 — intervention group
Group type: COMPARATOR
Intervention: Hepatic-arterial infusion plus systemic chemotherapy without bevacizumab (Bev)
Number of subjects: 49
Study 24646562 — intervention group
Group type: COMPARATOR
Intervention: Resected patients
Number of subjects: 49
Study 24647146 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive QFT-TB results
Number of subjects: 391
Study 24647146 — intervention group
Group type: COMPARATOR
Intervention: Negative or indeterminate QFT-TB results
Number of subjects: 391
Study 24647146 — intervention group
Group type: EXPERIMENTAL
Intervention: TST and QFT-TB
Number of subjects: 391
Study 24647146 — intervention group
Group type: COMPARATOR
Intervention: Positive TST
Number of subjects: 391
Study 24647146 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative TST with positive QFT-TB
Number of subjects: 391
Study 24647146 — intervention group
Group type: COMPARATOR
Intervention: Negative TST with negative or indeterminate QFT-TB
Number of subjects: 391
Study 24647218 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult ADHD Symptoms Self-Report (ASRS)
Number of subjects: 1171
Study 24647218 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential correlates of ADHD symptoms in relatives
Number of subjects: 1171
Study 24647275 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 359
Study 24647376 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album mother tincture (10 drops, 3 times a day for 12 weeks)
Number of subjects: 0
Study 24647390 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin B-6 (pyridoxal-5'-phosphate)
Number of subjects: 1976
Study 24647390 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine (μmol/L)
Number of subjects: 1976
Study 24647390 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PLP, RBC folate, homocysteine, and cysteine
Number of subjects: 1976
Study 24647390 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP, vitamin B-12, RBC folate, and homocysteine
Number of subjects: 1976
Study 24647390 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification by folic acid fortification period
Number of subjects: 1976
Study 24647408 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS guidelines for predicting infection or colonization with MDROs at ICU admission
Number of subjects: 610
Study 24647408 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS guidelines for predicting infection or colonization with MDROs at ICU discharge
Number of subjects: 610
Study 24647408 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS guidelines in departments with MDRO infection rates of 31-40%
Number of subjects: 610
Study 24647802 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated insular strokes
Number of subjects: 104
Study 24647802 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP levels
Number of subjects: 104
Study 24647802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression models including stroke location and MR-proANP levels
Number of subjects: 104
Study 24647849 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 24647849 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched diabetic patients)
Number of subjects: 20
Study 24649361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 75 µg with bupivacaine (group C)
Number of subjects: 90
Study 24649361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 0.5 mL with bupivacaine (group F)
Number of subjects: 90
Study 24649361 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal distilled water 0.5 mL with bupivacaine (group P)
Number of subjects: 90
Study 24649373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 105
Study 24649373 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Number of subjects: 105
Study 24649373 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FNA and Core Biopsy
Number of subjects: 105
Study 24649919 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 2 weeks
Number of subjects: 14
Study 24650638 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder physical activity (SPA) assessed by RT3 accelerometers
Number of subjects: 26
Study 24650638 — intervention group
Group type: COMPARATOR
Intervention: Improvement group
Number of subjects: 26
Study 24650809 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdecompression
Number of subjects: 0
Study 24650809 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 0
Study 24651258 — intervention group
Group type: COMPARATOR
Intervention: Pseudoxanthoma elasticum patients
Number of subjects: 75
Study 24651258 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 75
Study 24651570 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 56
Study 24651704 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 24652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (55%-75% maximum heart rate for 60 min, three times a week for 12 weeks)
Number of subjects: 35
Study 24652353 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 35
Study 24652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35
Study 24652992 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg administered every 3 weeks until progression or unacceptable toxicity
Number of subjects: 35
Study 24652994 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab-tiuxetan (Zevalin)
Number of subjects: 160
Study 24652994 — intervention group
Group type: COMPARATOR
Intervention: Historic control from MCL2 trial
Number of subjects: 160
Study 24653510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d) + Atorvastatin (10 mg/d)
Number of subjects: 125
Study 24653510 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 125
Study 24653510 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (2.5 mg/d)
Number of subjects: 125
Study 24653513 — intervention group
Group type: EXPERIMENTAL
Intervention: T40/A5
Number of subjects: 1814
Study 24653513 — intervention group
Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 1814
Study 24653513 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A5
Number of subjects: 1814
Study 24653513 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 1814
Study 24653513 — intervention group
Group type: EXPERIMENTAL
Intervention: T40-T80/A5-A10
Number of subjects: 1814
Study 24653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (transcutaneous electrical nerve stimulation) delivered via 2 electrodes on the venous cannulation site for 20 minutes before the procedure.
Number of subjects: 100
Study 24653515 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 100
Study 24653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 100
Study 24653515 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 100
Study 24653520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg)
Number of subjects: 64
Study 24653520 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% solution (control group)
Number of subjects: 64
Study 24653937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended-release 40-120mg/day
Number of subjects: 348
Study 24653937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 24654876 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold pacing output for VVI pacing after ≥2 documented PITs
Number of subjects: 550
Study 24654876 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold pacing output for VVI pacing
Number of subjects: 550
Study 24654876 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 550
Study 24655096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic unlimited recording electrocorticography-guided resective epilepsy surgery
Number of subjects: 5
Study 24655096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic unlimited recording electrocorticography (CURE)
Number of subjects: 5
Study 24655096 — intervention group
Group type: COMPARATOR
Intervention: RNS System (Responsive Neurostimulation System)
Number of subjects: 5
Study 24655096 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 5
Study 24655157 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention strategy to improve processes of end-of-life care
Number of subjects: 78
Study 24655157 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions that support staff's ability to convey compassion and communicate information
Number of subjects: 78
Study 24655689 — intervention group
Group type: EXPERIMENTAL
Intervention: SonR CRT optimization
Number of subjects: 876
Study 24655689 — intervention group
Group type: COMPARATOR
Intervention: Control arm (echocardiographic optimization)
Number of subjects: 876
Study 24655691 — intervention group
Group type: EXPERIMENTAL
Intervention: ORSIRO sirolimus-eluting stent with circumferential biodegradable coating
Number of subjects: 3540
Study 24655691 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY everolimus-eluting stent with abluminal biodegradable coating
Number of subjects: 3540
Study 24655691 — intervention group
Group type: COMPARATOR
Intervention: RESOLUTE INTEGRITY zotarolimus-eluting stent with durable coating
Number of subjects: 3540
Study 24655693 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week clopidogrel therapy
Number of subjects: 600
Study 24655693 — intervention group
Group type: COMPARATOR
Intervention: 6-month clopidogrel therapy
Number of subjects: 600
Study 24655871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding scale insulin to lower blood glucose levels (n = 145)
Number of subjects: 243
Study 24655871 — intervention group
Group type: COMPARATOR
Intervention: No insulin (n = 98)
Number of subjects: 243
Study 24656118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 14
Study 24656118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia with adenosine
Number of subjects: 14
Study 24656118 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 14
Study 24656509 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched low glycemic index diet with omega-3 PUFA supplementation
Number of subjects: 30
Study 24657065 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair (EVAR) using the Endurant endograft
Number of subjects: 290